No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Shanghai Allist Pharmaceuticals Co., Ltd. (SHSE:688578) Shares Could Be 33% Below Their Intrinsic Value Estimate
Alice: Shanghai Alice Pharmaceutical Technology Co., Ltd. 2024 Annual Performance Report Announcement
Shanghai Alice Pharmaceutical Technology Co., Ltd. 2024 Annual Results Express Announcement
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): In 2024, the net income reached 1.424 billion yuan, a year-on-year growth of 121.08%.
Gelonghui, February 25 - Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced its performance report for the 2024 fiscal year. During the reporting period, the company achieved a total operating income of 3,557.7779 million yuan, a year-on-year increase of 76.29%; the Net income attributable to the parent company's shareholders was 1,424.1242 million yuan, a year-on-year increase of 121.08%; the Net income attributable to the parent company's shareholders after deducting non-recurring gains and losses was 1,351.5186 million yuan, a year-on-year increase of 122.96%. The substantial increases were primarily due to the company’s product, methanesulfonic acid vumateen tablets (brand name "Aifsha"), achieving sales revenue of 350.
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Shareholders Might Be Looking For Exit